Menu Search
Equities

Ambu A/S

AMBU B:CPH

Ambu A/S

Actions
Health CareMedical Equipment and Services
  • Price (DKK)114.10
  • Today's Change0.150 / 0.13%
  • Shares traded285.78k
  • 1 Year change+26.33%
  • Beta1.0931
Data delayed at least 15 minutes, as of Nov 25 2024 15:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform1
Hold5
Sell1
Strong Sell0

Share price forecast in DKK

The 7 analysts offering 12 month price targets for Ambu A/S have a median target of 130.00, with a high estimate of 160.00 and a low estimate of 100.00. The median estimate represents a 14.09% increase from the last price of 113.95.
High40.4%160.00
Med14.1%130.00
Low-12.2%100.00

Dividends in DKK

In 2024, Ambu A/S reported a dividend of 0.38 DKK. The 3 analysts covering the company expect dividends of 0.42 DKK for the upcoming fiscal year, an increase of 9.74%.
Div growth (TTM)--
More ▼

Earnings history & estimates in DKK

On Nov 04, 2024, Ambu A/S reported 4th quarter 2024 losses of -0.51 per share.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate+17.65%
Ambu A/S reported annual 2024 earnings of 0.88 per share on Nov 04, 2024.
Average growth rate-0.04%
More ▼

Revenue history & estimates in DKK

Ambu A/S had 4th quarter 2024 revenues of 1.39bn. This missed the 1.41bn consensus estimate of the 2 analysts following the company. This was 22.53% above the prior year's 4th quarter results.
Average growth rate+2.52%
Ambu A/S had revenues for the full year 2024 of 5.39bn. This was 12.90% above the prior year's results.
Average growth rate+10.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.